Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
about
Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel diseaseAzathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
P2860
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Oral administration of non-abs ...... blind Phase II clinical trial.
@en
Oral administration of non-abs ...... blind Phase II clinical trial.
@nl
type
label
Oral administration of non-abs ...... blind Phase II clinical trial.
@en
Oral administration of non-abs ...... blind Phase II clinical trial.
@nl
prefLabel
Oral administration of non-abs ...... blind Phase II clinical trial.
@en
Oral administration of non-abs ...... blind Phase II clinical trial.
@nl
P2093
P2860
P356
P1476
Oral administration of non-abs ...... blind Phase II clinical trial.
@en
P2093
A Ben Ya'acov
E Nussinson
F Konikoff
P2860
P304
P356
10.1111/CEI.12640
P577
2015-08-01T00:00:00Z